Research programme: antibodies - Prestige BioPharmaAlternative Names: PBP 1510
Latest Information Update: 18 Jan 2017
At a glance
- Originator Prestige BioPharma
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Pancreatic cancer
Most Recent Events
- 18 Jan 2017 Early research in Pancreatic cancer in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)